# Building the evidence-based value story
A device gets FDA clearance, the sales team celebrates, and then it barely sells. This happens more often than most people outside the sector realize.
Consider the common pattern: a company earns 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.View full definition →) clearance (the FDA pathway that lets a device reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → market by showing it is "substantially equivalent" to a product already sold). Clearance means the device is legally sellable. It does not mean anyone has proven it works better than what a hospital already owns. When the sales rep walks into a purchasing committee and cannot answer "compared to what?", the deal stalls.
In biotech and medtech, regulatory approval is the price of entry, not the winning argument. The winning argument is evidence. This lesson shows you how to turn clinical data into a message architecture that survives scrutiny from clinicians, payers, and procurement.
Regulatory approval and commercial value answer different questions.
A payer is the entity that pays for care: an insurer, a national health system, or an employer plan. Payers do not care that you are cleared. They care whether your product reduces cost, complications, or readmissions relative to the alternative.
So the first mistake to avoid: building marketing around "FDA cleared" as if it were a differentiator. It is table stakes. Everyone in your category has it.
The device in our opening scene had no comparative clinical data: no head to head study against the standard of care, no outcomes showing it was faster, safer, or cheaper. Absent that, buyers default to the incumbent.
Comparative evidence usually comes in tiers, from weakest to strongest:
1. Bench testing and animal data (useful for regulators, weak for marketing)
2. Single-arm clinical studies (your device only, no comparison)
3. Retrospective or registry data (real-world, but not randomized)
4. Randomized controlled trials, or RCTs (the gold standard: patients randomly assigned to your product or the comparator)
Your marketing is only as strong as the tier of evidence behind it. A claim backed by an RCT published in a respected journal is a fundamentally different asset than a claim backed by a lab bench test.
Think of your value story as a pyramid. Each layer sits on the one below it. If a lower layer is missing, the top collapses under questioning.
An endpoint is the specific, pre-defined outcome a trial measures. Examples: 30-day mortality, infection rate, time to healing, progression-free survival (how long a cancer patient lives without the disease worsening).
Your marketing claims must trace directly back to a measured endpoint. Not a hope. A number that appeared in a peer-reviewed paper.
Bad: "Our stent improves patient outcomes."
Good: "In [published trial], the device reduced target lesion revascularization at 12 months versus the control arm."
The second sentence is defensible. A cardiologist can look up the paper. That credibility is the entire point.
Translate the endpoint into a claim clinicians care about. This is where you convert statistics into meaning, without overreaching.
Watch the difference between relative and absolute effect. If a complication drops from 2% to 1%, that is a 50% relative reduction but only a 1 percentage point absolute reduction. Both are true. Regulators and sophisticated buyers will notice if you cite only the flattering relative number. Cite both. It builds trust and keeps you compliant.
Now translate clinical benefit into money, because procurement and payers think in budgets. This is health economics: fewer infections mean fewer extra hospital days, which means lower cost per patient.
Keep economic claims tied to the clinical data. A cost model built on a real endpoint (say, a measured reduction in readmissions) is credible. A cost model built on assumptions is a spreadsheet, and buyers know the difference.
Only now do you write the tagline. It sits on top of three proven layers. If someone challenges the tagline, you can walk them down the pyramid to the published endpoint.
🎬 [VIDEO: "How to Read a Clinical Trial Paper" — youtube.com — a clear walkthrough of endpoints, control arms, and statistical significance for non-scientists]
Different buyers weight evidence differently. One message does not fit all.
They trust peer-reviewed journals and guidelines. Lead with the endpoint, the study design, and the journal. Name the comparator. Physicians are trained to ask "versus what, and how many patients?"
They want cost effectiveness and budget impact. In some markets, formal bodies assess this. The UK's National Institute for Health and Care Excellence (NICE) publishes public appraisals of whether a technology is worth funding. You can read real examples of how evidence is judged at NICE guidance. Studying these teaches you exactly what evidence bar serious payers set.
They want risk reduction: proven track record, real-world data, references from comparable institutions. A registry showing 5,000 real patients can outweigh a small pristine RCT here, because it speaks to reliability at scale.
You cannot say whatever the data hints at. In the US, the FDA regulates promotional claims. A cleared or approved product can generally only be marketed for its on-label use (the specific indication the FDA authorized). Promoting off-label uses (unapproved applications) is a serious compliance risk.
Practical rules for marketers:
The claims matrix is the single most useful artifact a biotech or medtech marketer maintains. It is what lets legal approve a campaign in days instead of weeks.
Knowledge check
1. Why does the lesson argue that regulatory clearance is 'the price of entry, not the winning argument'?
2. A sales rep stalls when a purchasing committee asks 'compared to what?'. What underlying gap does this reveal?
3. When evaluating a new device, what does a payer fundamentally care about?
4. Select ALL correct answers. Which claims accurately distinguish the question 'approval' answers from the question 'value' answers?
Select all the correct answers.
5. Select ALL correct answers. Which of the following are reasons that marketing built around 'FDA cleared' fails as a value differentiator?
Select all the correct answers.
Not every product launches with an RCT. Trials are expensive and slow. So what do you do when the strongest evidence you have is a single-arm study or bench data?
Be honest and be narrow.
Narrow the claim to what the data supports. If you only have a single-arm study, do not imply superiority over a competitor. Claim what you measured: "achieved X result in Y patients." Precise and modest beats broad and challengeable.
Sequence your evidence generation. Treat evidence as a roadmap that runs alongside commercialization:
Many successful products launch on modest evidence and strengthen the story over two to three years. Marketing and clinical affairs should plan this jointly from day one.
Use real-world evidence deliberately. Real-world evidence, or RWE, is data from routine clinical use (registries, electronic health records, claims data). Regulators and payers increasingly accept well-designed RWE. It is often faster and cheaper to gather than an RCT, and it answers the "does it work in messy real life?" question that pristine trials cannot.
Ask three questions:
1. What endpoint, in what study, supports this exact sentence?
2. Is the comparison fair (right comparator, absolute and relative numbers)?
3. Is this within the approved label?
If you cannot answer all three, the claim is not ready.
Return to the failed launch. The fix was never a better tagline or a bigger ad budget. The fix was evidence: a comparative study answering "why switch?" A value story is a structure that carries proof from a journal page to a purchasing decision. Build the pyramid from the endpoint up, match the evidence to each audience, and stay inside your label.